1 Study Coverage
    1.1 Neuraminidase Inhibitor Product Introduction
    1.2 Market by Type
        1.2.1 Global Neuraminidase Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Zanamivir
        1.2.3 Oseltamivir
        1.2.4 Peramivir
        1.2.5 Laninamivir
    1.3 Market by Application
        1.3.1 Global Neuraminidase Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital Pharmacies
        1.3.3 Drug Stores
        1.3.4 Retail Stores
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Neuraminidase Inhibitor Sales Estimates and Forecasts 2017-2028
    2.2 Global Neuraminidase Inhibitor Revenue Estimates and Forecasts 2017-2028
    2.3 Global Neuraminidase Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Neuraminidase Inhibitor Sales by Region
        2.4.1 Global Neuraminidase Inhibitor Sales by Region (2017-2022)
        2.4.2 Global Sales Neuraminidase Inhibitor by Region (2023-2028)
    2.5 Global Neuraminidase Inhibitor Revenue by Region
        2.5.1 Global Neuraminidase Inhibitor Revenue by Region (2017-2022)
        2.5.2 Global Neuraminidase Inhibitor Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Neuraminidase Inhibitor Sales by Manufacturers
        3.1.1 Global Top Neuraminidase Inhibitor Manufacturers by Sales (2017-2022)
        3.1.2 Global Neuraminidase Inhibitor Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neuraminidase Inhibitor in 2021
    3.2 Global Neuraminidase Inhibitor Revenue by Manufacturers
        3.2.1 Global Neuraminidase Inhibitor Revenue by Manufacturers (2017-2022)
        3.2.2 Global Neuraminidase Inhibitor Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitor Revenue in 2021
    3.3 Global Neuraminidase Inhibitor Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Neuraminidase Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Neuraminidase Inhibitor Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Neuraminidase Inhibitor Sales by Type
        4.1.1 Global Neuraminidase Inhibitor Historical Sales by Type (2017-2022)
        4.1.2 Global Neuraminidase Inhibitor Forecasted Sales by Type (2023-2028)
        4.1.3 Global Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    4.2 Global Neuraminidase Inhibitor Revenue by Type
        4.2.1 Global Neuraminidase Inhibitor Historical Revenue by Type (2017-2022)
        4.2.2 Global Neuraminidase Inhibitor Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    4.3 Global Neuraminidase Inhibitor Price by Type
        4.3.1 Global Neuraminidase Inhibitor Price by Type (2017-2022)
        4.3.2 Global Neuraminidase Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Neuraminidase Inhibitor Sales by Application
        5.1.1 Global Neuraminidase Inhibitor Historical Sales by Application (2017-2022)
        5.1.2 Global Neuraminidase Inhibitor Forecasted Sales by Application (2023-2028)
        5.1.3 Global Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    5.2 Global Neuraminidase Inhibitor Revenue by Application
        5.2.1 Global Neuraminidase Inhibitor Historical Revenue by Application (2017-2022)
        5.2.2 Global Neuraminidase Inhibitor Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    5.3 Global Neuraminidase Inhibitor Price by Application
        5.3.1 Global Neuraminidase Inhibitor Price by Application (2017-2022)
        5.3.2 Global Neuraminidase Inhibitor Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Neuraminidase Inhibitor Market Size by Type
        6.1.1 North America Neuraminidase Inhibitor Sales by Type (2017-2028)
        6.1.2 North America Neuraminidase Inhibitor Revenue by Type (2017-2028)
    6.2 North America Neuraminidase Inhibitor Market Size by Application
        6.2.1 North America Neuraminidase Inhibitor Sales by Application (2017-2028)
        6.2.2 North America Neuraminidase Inhibitor Revenue by Application (2017-2028)
    6.3 North America Neuraminidase Inhibitor Market Size by Country
        6.3.1 North America Neuraminidase Inhibitor Sales by Country (2017-2028)
        6.3.2 North America Neuraminidase Inhibitor Revenue by Country (2017-2028)
        6.3.3 United States
        6.3.4 Canada
7 Europe
    7.1 Europe Neuraminidase Inhibitor Market Size by Type
        7.1.1 Europe Neuraminidase Inhibitor Sales by Type (2017-2028)
        7.1.2 Europe Neuraminidase Inhibitor Revenue by Type (2017-2028)
    7.2 Europe Neuraminidase Inhibitor Market Size by Application
        7.2.1 Europe Neuraminidase Inhibitor Sales by Application (2017-2028)
        7.2.2 Europe Neuraminidase Inhibitor Revenue by Application (2017-2028)
    7.3 Europe Neuraminidase Inhibitor Market Size by Country
        7.3.1 Europe Neuraminidase Inhibitor Sales by Country (2017-2028)
        7.3.2 Europe Neuraminidase Inhibitor Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Neuraminidase Inhibitor Market Size by Type
        8.1.1 Asia Pacific Neuraminidase Inhibitor Sales by Type (2017-2028)
        8.1.2 Asia Pacific Neuraminidase Inhibitor Revenue by Type (2017-2028)
    8.2 Asia Pacific Neuraminidase Inhibitor Market Size by Application
        8.2.1 Asia Pacific Neuraminidase Inhibitor Sales by Application (2017-2028)
        8.2.2 Asia Pacific Neuraminidase Inhibitor Revenue by Application (2017-2028)
    8.3 Asia Pacific Neuraminidase Inhibitor Market Size by Region
        8.3.1 Asia Pacific Neuraminidase Inhibitor Sales by Region (2017-2028)
        8.3.2 Asia Pacific Neuraminidase Inhibitor Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 China Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
9 Latin America
    9.1 Latin America Neuraminidase Inhibitor Market Size by Type
        9.1.1 Latin America Neuraminidase Inhibitor Sales by Type (2017-2028)
        9.1.2 Latin America Neuraminidase Inhibitor Revenue by Type (2017-2028)
    9.2 Latin America Neuraminidase Inhibitor Market Size by Application
        9.2.1 Latin America Neuraminidase Inhibitor Sales by Application (2017-2028)
        9.2.2 Latin America Neuraminidase Inhibitor Revenue by Application (2017-2028)
    9.3 Latin America Neuraminidase Inhibitor Market Size by Country
        9.3.1 Latin America Neuraminidase Inhibitor Sales by Country (2017-2028)
        9.3.2 Latin America Neuraminidase Inhibitor Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Neuraminidase Inhibitor Market Size by Type
        10.1.1 Middle East and Africa Neuraminidase Inhibitor Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Neuraminidase Inhibitor Revenue by Type (2017-2028)
    10.2 Middle East and Africa Neuraminidase Inhibitor Market Size by Application
        10.2.1 Middle East and Africa Neuraminidase Inhibitor Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Neuraminidase Inhibitor Revenue by Application (2017-2028)
    10.3 Middle East and Africa Neuraminidase Inhibitor Market Size by Country
        10.3.1 Middle East and Africa Neuraminidase Inhibitor Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 GlaxoSmithKline
        11.1.1 GlaxoSmithKline Corporation Information
        11.1.2 GlaxoSmithKline Overview
        11.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 GlaxoSmithKline Recent Developments
    11.2 Gilead Sciences
        11.2.1 Gilead Sciences Corporation Information
        11.2.2 Gilead Sciences Overview
        11.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Gilead Sciences Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Gilead Sciences Recent Developments
    11.3 F. Hoffman-La Roche
        11.3.1 F. Hoffman-La Roche Corporation Information
        11.3.2 F. Hoffman-La Roche Overview
        11.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 F. Hoffman-La Roche Recent Developments
    11.4 BioCryst
        11.4.1 BioCryst Corporation Information
        11.4.2 BioCryst Overview
        11.4.3 BioCryst Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 BioCryst Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 BioCryst Recent Developments
    11.5 Daiichi Sankyo
        11.5.1 Daiichi Sankyo Corporation Information
        11.5.2 Daiichi Sankyo Overview
        11.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Daiichi Sankyo Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Daiichi Sankyo Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Neuraminidase Inhibitor Industry Chain Analysis
    12.2 Neuraminidase Inhibitor Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Neuraminidase Inhibitor Production Mode & Process
    12.4 Neuraminidase Inhibitor Sales and Marketing
        12.4.1 Neuraminidase Inhibitor Sales Channels
        12.4.2 Neuraminidase Inhibitor Distributors
    12.5 Neuraminidase Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Neuraminidase Inhibitor Industry Trends
    13.2 Neuraminidase Inhibitor Market Drivers
    13.3 Neuraminidase Inhibitor Market Challenges
    13.4 Neuraminidase Inhibitor Market Restraints
14 Key Findings in The Global Neuraminidase Inhibitor Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Neuraminidase Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Zanamivir
    Table 3. Major Manufacturers of Oseltamivir
    Table 4. Major Manufacturers of Peramivir
    Table 5. Major Manufacturers of Laninamivir
    Table 6. Global Neuraminidase Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Neuraminidase Inhibitor Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Neuraminidase Inhibitor Sales by Region (2017-2022) & (K Units)
    Table 9. Global Neuraminidase Inhibitor Sales Market Share by Region (2017-2022)
    Table 10. Global Neuraminidase Inhibitor Sales by Region (2023-2028) & (K Units)
    Table 11. Global Neuraminidase Inhibitor Sales Market Share by Region (2023-2028)
    Table 12. Global Neuraminidase Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Neuraminidase Inhibitor Revenue Market Share by Region (2017-2022)
    Table 14. Global Neuraminidase Inhibitor Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Neuraminidase Inhibitor Revenue Market Share by Region (2023-2028)
    Table 16. Global Neuraminidase Inhibitor Sales by Manufacturers (2017-2022) & (K Units)
    Table 17. Global Neuraminidase Inhibitor Sales Share by Manufacturers (2017-2022)
    Table 18. Global Neuraminidase Inhibitor Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Neuraminidase Inhibitor Revenue Share by Manufacturers (2017-2022)
    Table 20. Neuraminidase Inhibitor Price by Manufacturers (2017-2022) &(US$/Unit)
    Table 21. Global Neuraminidase Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Neuraminidase Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitor as of 2021)
    Table 23. Neuraminidase Inhibitor Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Neuraminidase Inhibitor Product Offered
    Table 25. Date of Manufacturers Enter into Neuraminidase Inhibitor Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 28. Global Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 29. Global Neuraminidase Inhibitor Sales Share by Type (2017-2022)
    Table 30. Global Neuraminidase Inhibitor Sales Share by Type (2023-2028)
    Table 31. Global Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Neuraminidase Inhibitor Revenue Share by Type (2017-2022)
    Table 34. Global Neuraminidase Inhibitor Revenue Share by Type (2023-2028)
    Table 35. Neuraminidase Inhibitor Price by Type (2017-2022) & (US$/Unit)
    Table 36. Global Neuraminidase Inhibitor Price Forecast by Type (2023-2028) & (US$/Unit)
    Table 37. Global Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 38. Global Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 39. Global Neuraminidase Inhibitor Sales Share by Application (2017-2022)
    Table 40. Global Neuraminidase Inhibitor Sales Share by Application (2023-2028)
    Table 41. Global Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Neuraminidase Inhibitor Revenue Share by Application (2017-2022)
    Table 44. Global Neuraminidase Inhibitor Revenue Share by Application (2023-2028)
    Table 45. Neuraminidase Inhibitor Price by Application (2017-2022) & (US$/Unit)
    Table 46. Global Neuraminidase Inhibitor Price Forecast by Application (2023-2028) & (US$/Unit)
    Table 47. North America Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 48. North America Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 49. North America Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 52. North America Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 53. North America Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
    Table 56. North America Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
    Table 57. North America Neuraminidase Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Neuraminidase Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 60. Europe Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 61. Europe Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 64. Europe Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 65. Europe Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
    Table 68. Europe Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
    Table 69. Europe Neuraminidase Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Neuraminidase Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 72. Asia Pacific Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 73. Asia Pacific Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 76. Asia Pacific Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 77. Asia Pacific Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Neuraminidase Inhibitor Sales by Region (2017-2022) & (K Units)
    Table 80. Asia Pacific Neuraminidase Inhibitor Sales by Region (2023-2028) & (K Units)
    Table 81. Asia Pacific Neuraminidase Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Neuraminidase Inhibitor Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 84. Latin America Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 85. Latin America Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 88. Latin America Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 89. Latin America Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
    Table 92. Latin America Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
    Table 93. Latin America Neuraminidase Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Neuraminidase Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Neuraminidase Inhibitor Sales by Type (2017-2022) & (K Units)
    Table 96. Middle East and Africa Neuraminidase Inhibitor Sales by Type (2023-2028) & (K Units)
    Table 97. Middle East and Africa Neuraminidase Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Neuraminidase Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Neuraminidase Inhibitor Sales by Application (2017-2022) & (K Units)
    Table 100. Middle East and Africa Neuraminidase Inhibitor Sales by Application (2023-2028) & (K Units)
    Table 101. Middle East and Africa Neuraminidase Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Neuraminidase Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Neuraminidase Inhibitor Sales by Country (2017-2022) & (K Units)
    Table 104. Middle East and Africa Neuraminidase Inhibitor Sales by Country (2023-2028) & (K Units)
    Table 105. Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 107. GlaxoSmithKline Corporation Information
    Table 108. GlaxoSmithKline Description and Major Businesses
    Table 109. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 110. GlaxoSmithKline Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. GlaxoSmithKline Recent Developments
    Table 112. Gilead Sciences Corporation Information
    Table 113. Gilead Sciences Description and Major Businesses
    Table 114. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 115. Gilead Sciences Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Gilead Sciences Recent Developments
    Table 117. F. Hoffman-La Roche Corporation Information
    Table 118. F. Hoffman-La Roche Description and Major Businesses
    Table 119. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 120. F. Hoffman-La Roche Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. F. Hoffman-La Roche Recent Developments
    Table 122. BioCryst Corporation Information
    Table 123. BioCryst Description and Major Businesses
    Table 124. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 125. BioCryst Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. BioCryst Recent Developments
    Table 127. Daiichi Sankyo Corporation Information
    Table 128. Daiichi Sankyo Description and Major Businesses
    Table 129. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 130. Daiichi Sankyo Neuraminidase Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Daiichi Sankyo Recent Developments
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Neuraminidase Inhibitor Distributors List
    Table 135. Neuraminidase Inhibitor Customers List
    Table 136. Neuraminidase Inhibitor Market Trends
    Table 137. Neuraminidase Inhibitor Market Drivers
    Table 138. Neuraminidase Inhibitor Market Challenges
    Table 139. Neuraminidase Inhibitor Market Restraints
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neuraminidase Inhibitor Product Picture
    Figure 3. Global Neuraminidase Inhibitor Market Share by Type in 2021 & 2028
    Figure 3. Zanamivir Product Picture
    Figure 4. Oseltamivir Product Picture
    Figure 5. Peramivir Product Picture
    Figure 6. Laninamivir Product Picture
    Figure 7. Global Neuraminidase Inhibitor Market Share by Application in 2021 & 2028
    Figure 8. Hospital Pharmacies
    Figure 9. Drug Stores
    Figure 10. Retail Stores
    Figure 11. Others
    Figure 12. Neuraminidase Inhibitor Report Years Considered
    Figure 13. Global Neuraminidase Inhibitor Sales 2017-2028 (K Units)
    Figure 14. Global Neuraminidase Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Neuraminidase Inhibitor Revenue 2017-2028 (US$ Million)
    Figure 16. Global Neuraminidase Inhibitor Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 17. Global Neuraminidase Inhibitor Sales Market Share by Region (2017-2022)
    Figure 18. Global Neuraminidase Inhibitor Sales Market Share by Region (2023-2028)
    Figure 19. North America Neuraminidase Inhibitor Sales YoY (2017-2028) & (K Units)
    Figure 20. North America Neuraminidase Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Europe Neuraminidase Inhibitor Sales YoY (2017-2028) & (K Units)
    Figure 22. Europe Neuraminidase Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Asia-Pacific Neuraminidase Inhibitor Sales YoY (2017-2028) & (K Units)
    Figure 24. Asia-Pacific Neuraminidase Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Latin America Neuraminidase Inhibitor Sales YoY (2017-2028) & (K Units)
    Figure 26. Latin America Neuraminidase Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Middle East & Africa Neuraminidase Inhibitor Sales YoY (2017-2028) & (K Units)
    Figure 28. Middle East & Africa Neuraminidase Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. The Neuraminidase Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 30. The Top 5 and 10 Largest Manufacturers of Neuraminidase Inhibitor in the World: Market Share by Neuraminidase Inhibitor Revenue in 2021
    Figure 31. Global Neuraminidase Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 32. Global Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 33. Global Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 34. Global Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 35. Global Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 36. North America Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 37. North America Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 38. North America Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 39. North America Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 40. North America Neuraminidase Inhibitor Sales Share by Country (2017-2028)
    Figure 41. North America Neuraminidase Inhibitor Revenue Share by Country (2017-2028)
    Figure 42. United States Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 43. Canada Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 44. Europe Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 45. Europe Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 46. Europe Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 47. Europe Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 48. Europe Neuraminidase Inhibitor Sales Share by Country (2017-2028)
    Figure 49. Europe Neuraminidase Inhibitor Revenue Share by Country (2017-2028)
    Figure 50. Germany Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 51. France Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 52. U.K. Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 53. Italy Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 54. Russia Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 55. Asia Pacific Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Neuraminidase Inhibitor Sales Share by Region (2017-2028)
    Figure 60. Asia Pacific Neuraminidase Inhibitor Revenue Share by Region (2017-2028)
    Figure 61. China Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 62. Japan Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 63. South Korea Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 64. India Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 65. Australia Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 66. China Taiwan Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 67. Indonesia Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 68. Thailand Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 69. Malaysia Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 70. Latin America Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 71. Latin America Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 72. Latin America Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 73. Latin America Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 74. Latin America Neuraminidase Inhibitor Sales Share by Country (2017-2028)
    Figure 75. Latin America Neuraminidase Inhibitor Revenue Share by Country (2017-2028)
    Figure 76. Mexico Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 77. Brazil Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 78. Argentina Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 79. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Neuraminidase Inhibitor Sales Share by Country (2017-2028)
    Figure 84. Middle East and Africa Neuraminidase Inhibitor Revenue Share by Country (2017-2028)
    Figure 85. Turkey Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 86. Saudi Arabia Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 87. UAE Neuraminidase Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 88. Neuraminidase Inhibitor Value Chain
    Figure 89. Neuraminidase Inhibitor Production Process
    Figure 90. Channels of Distribution
    Figure 91. Distributors Profiles
    Figure 92. Bottom-up and Top-down Approaches for This Report
    Figure 93. Data Triangulation
    Figure 94. Key Executives Interviewed